Trastuzumab-Associated Flagellate Erythema: Report in a Woman with Metastatic Breast Cancer and Review of Antineoplastic Therapy-Induced Flagellate Dermatoses

Cohen, Philip R.

doi:10.1007/s13555-015-0085-2

Cited by 25 publications

(30 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the authors reviewed the salient features of bleomycin‐induced flagellate erythema. I have also recently described an oncology patient who developed flagellate erythema while receiving trastuzumab for the treatment of her metastatic breast cancer …”

Section: Antineoplastic Therapy‐associated Flagellate Dermatosesmentioning

confidence: 99%

“…are credited with the initial description of bleomycin‐induced flagellate erythema in oncology patients . This unique reaction to bleomycin may be observed in patients with germ cell tumors or Hodgkin's lymphoma who are treated with 5–465 IU of the drug . The lesions are often pruritic and appear within less than 1 day to 9 weeks after initiating therapy …”

Section: Antineoplastic Therapy‐associated Flagellate Dermatosesmentioning

confidence: 99%

“…In addition to bleomycin, antineoplastic therapy‐induced flagellate dermatoses (presenting as erythema or dermatitis) have also been described in oncology patients who have received other agents (Table ) . Flagellate dermatitis was observed in several individuals who received intravenous peplomycin (a bleomycin analog) as part of combination chemotherapy for various neoplasms .…”

Section: Antineoplastic Therapy‐associated Flagellate Dermatosesmentioning

confidence: 99%

“…Flagellate dermatitis was observed in several individuals who received intravenous peplomycin (a bleomycin analog) as part of combination chemotherapy for various neoplasms . Flagellate dermatoses were also reported, albeit only in single case reports, in patients who were treated with bendamustine (for chronic lymphocytic leukemia), docetaxel (for breast cancer), and trastuzumab (for breast cancer) …”

Section: Antineoplastic Therapy‐associated Flagellate Dermatosesmentioning

confidence: 99%

“…Similar to bleomycin‐induced flagellate erythema, pruritus is typically associated with flagellate dermatoses secondary to other antineoplastic agents . The appearance of the condition also varied.…”

Section: Antineoplastic Therapy‐associated Flagellate Dermatosesmentioning

confidence: 99%

See 4 more Smart Citations

Antineoplastic therapy‐associated flagellate dermatoses

Cohen

2017

Int J Dermatology

Self Cite

View full text Add to dashboard Cite

Section: Antineoplastic Therapy‐associated Flagellate Dermatosesmentioning

confidence: 99%

Section: Antineoplastic Therapy‐associated Flagellate Dermatosesmentioning

confidence: 99%

Section: Antineoplastic Therapy‐associated Flagellate Dermatosesmentioning

confidence: 99%

Section: Antineoplastic Therapy‐associated Flagellate Dermatosesmentioning

confidence: 99%

Section: Antineoplastic Therapy‐associated Flagellate Dermatosesmentioning

confidence: 99%

See 3 more Smart Citations

Antineoplastic therapy‐associated flagellate dermatoses

Cohen

2017

Int J Dermatology

Self Cite

View full text Add to dashboard Cite

A closer look at chemotherapy‐induced flagellate dermatitis

Constantinou

Kotecha

Laouris

et al. 2022

Skin Health and Disease

View full text Add to dashboard Cite

Background: Flagellate dermatitis (FD) is a rare skin rash, which may occur following the administration of antineoplastic agents. It has been reported following the administration of bleomycin, docetaxel, trastuzumab, cisplatin, bendamustine and doxorubicin. We provide a summary of the epidemiology, aetiology, pathophysiology, and distribution of chemotherapy-induced FD. Methods: PubMed was searched using ((flagellat*) AND (Dermat*)) OR ((Flagellat*) AND (Erythema)). The search yielded 206 publications, out of which 54 individual case reports were identified which fulfilled our inclusion criteria. Statistical analysis was performed where appropriate. Results: Female patients were slightly more likely to develop FD compared to males. In the majority of cases FD appeared on the upper and lower limbs and pruritus was an accompanying feature in 51% of cases. Most cases developed after the first cycle of chemotherapy and females were statistically more likely to present within the first 72 hr (p <0.05). Skin biopsies were taken in 41% of cases and this was not statistically associated with the patient's gender, (p = 0.651), presentation within 72 hr (p = 0.076) or cancer diagnosis. Chemotherapy was stopped in 62% of patients and was associated with female gender (p = 0.0098). Most patients who received treatment were managed with topical steroids. Time for rash resolution ranged from a few weeks to four months following the discontinuation of the causative drug. Conclusion: FD is a rare adverse skin effect of chemotherapeutic treatment, most commonly presenting on the upper and lower limbs of patients following their first cycle of chemotherapy. Early presentation is more common in females leading to increased likelihood of stopping chemotherapy. Biopsy findings poorly correlate with disease severity. Continuation of chemotherapy treatment in combination with topical steroids may not adversely affect rash resolution. | INTRODUCTIONFlagellate dermatitis (FD) is a rare skin rash, which can occur following the administration of antineoplastic agents. It is estimated that FD occurs in 1%-2% of oncology patients. 1 Bleomycin has historically been associated with FD, and was first described in 1970. 2 The reported incidence in bleomycin-treated patients Anastasia Constantinou and Deeya Kotecha are the joint first authors.

show abstract